Famotidine-<sup>13</sup>C-d<sub>3</sub>

Famotidine-13C-d3

CAT N°: 31493
Price:

787.00 668.95

Famotidine-13C-d3 is intended for use as an internal standard for the quantification of famotidine (Item No. 23828) by GC- or LC-MS. Famotidine is a histamine H2 receptor antagonist with a Ki value of 12 nM in fractionated guinea pig cerebral cortex membranes.{36463} It is selective for H2 over H1 and muscarinic receptors (Kis = 4 and 28 µM, respectively, in bovine cerebral cortex).{23214} Famotidine inhibits histamine-induced acid secretion in isolated canine parietal cells (IC50 = 0.6 µM).{17620} It also suppresses histamine-induced gastric acid secretion in dogs when administered orally and in anesthetized rats when administered intraduodenally (ID50s = 10 and 400 µg/kg, respectively).{17620} Formulations containing famotidine have been used in the treatment of ulcers, gastroesophageal reflux disease (GERD), and heartburn, as well as to decrease the risk of gastrointestinal toxicity associated with non-steroidal anti-inflammatory drugs (NSAIDs).

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 3-[[[2-[(aminoiminomethyl)amino]-4-thiazolyl]methyl]thio]-N-(aminosulfonyl)-propanimidamide1-13C-2,3,3-d3
  • Correlated keywords
    • deuterated deuterium GCMS LCMS H-1 2
  • Product Overview:
    Famotidine-13C-d3 is intended for use as an internal standard for the quantification of famotidine (Item No. 23828) by GC- or LC-MS. Famotidine is a histamine H2 receptor antagonist with a Ki value of 12 nM in fractionated guinea pig cerebral cortex membranes.{36463} It is selective for H2 over H1 and muscarinic receptors (Kis = 4 and 28 µM, respectively, in bovine cerebral cortex).{23214} Famotidine inhibits histamine-induced acid secretion in isolated canine parietal cells (IC50 = 0.6 µM).{17620} It also suppresses histamine-induced gastric acid secretion in dogs when administered orally and in anesthetized rats when administered intraduodenally (ID50s = 10 and 400 µg/kg, respectively).{17620} Formulations containing famotidine have been used in the treatment of ulcers, gastroesophageal reflux disease (GERD), and heartburn, as well as to decrease the risk of gastrointestinal toxicity associated with non-steroidal anti-inflammatory drugs (NSAIDs).

We also advise you